NCT02428504

Brief Summary

It is not universal that terminally ill patients choose surrogate in the event of disagreement between the treating physician and the surrogate at the end of their lives. There are several factors that influence the terminally ill patient's decision to choose a decision maker at the end of his / life.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
148

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2012

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2012

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

October 15, 2012

Completed
2.5 years until next milestone

First Posted

Study publicly available on registry

April 28, 2015

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

March 9, 2016

Status Verified

March 1, 2016

Enrollment Period

3.5 years

First QC Date

October 15, 2012

Last Update Submit

March 8, 2016

Conditions

Terminal Diseases

Keywords

Questionnaire

Outcome Measures

Primary Outcomes (1)

  • DECISION MAKING IN END OF LIFE: INDIVIDUALS PREFERENCES

    Individual Preferences

    1 year

Secondary Outcomes (1)

  • DECISION MAKING IN END OF LIFE: INDIVIDUALS PREFERENCES

    1 year

Study Arms (1)

End of life decision

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients from Oncology, Pulmonary and Heart Failure.

You may qualify if:

  • Non-resectable malignancy undergoing palliative care treatment
  • Severe end stage COPD with FEV1 \< 30% and receiving home O2 for \> six months
  • End stage cardiomyopathy NYHA class III/IV, not candidate for heart transplantation.

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St. Luke's Roosevelt Hospital Center

New York, New York, 10019, United States

Location

Study Officials

  • Hassan Khouli, MD

    St. Luke's-Roosevelt Hospital Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 15, 2012

First Posted

April 28, 2015

Study Start

June 1, 2012

Primary Completion

December 1, 2015

Study Completion

December 1, 2015

Last Updated

March 9, 2016

Record last verified: 2016-03

Locations

US(1)